Mufaso, as you know, the VK2735 oral phase 1 has 5 cohorts: placebo, 2.5, 5, 10, and 20mg/day. For the 20mg/day cohort, that's 140mg/week in oral compared with 15mg/week SQ in VENTURE for the highest dose. That's 9 times more VK2735 in a patient's body in a week. Given the long half-life of 2735, would be interesting to find out VK2735 oral pill's effect on efficacy and tolerability. Do you think Brian Lian's 50-60% estimated degradation in absorption from SQ to the oral pill is a comparison between one VK 2735 oral pill Vs one VK 2735 SQ injection of the same dosage?
News 
Market Data 
Discover 
